RSS   Newsletter   Contact   Advertise with us

ACell names Patrick McBrayer chief executive officer

Staff writer | Columbia, Md., USA | January 12, 2016
ACellJanuary 12, 2016, Columbia, Md., USA - ACell, Inc., a biotechnology company, announced that it has named Patrick McBrayer president and chief executive officer.
Mr. McBrayer has more than 20 years of healthcare senior management experience. He currently serves on the Board of Directors of Misonix, Inc. and was President and CEO of AxioMed Spine Corporation until the company was acquired in 2014.

Mr. McBrayer is on the Board of Directors of Misonix Inc, which markets therapeutic ultrasound medical devices world-wide. He has recently advised medical device companies in spine, orthopedics and biotechnology.

Prior to AxioMed, Mr. McBrayer was Chief Executive Officer of Xylos Corporation, a medical biomaterials company. He was also a Founder of Transave Inc. (now Insmed Inc.), a biotechnology company focused on the site specific treatment of lung disease.

Prior to joining Xylos, he served as President and CEO of Exogen, Inc., a company focused on the non-invasive treatment of musculoskeletal injury and disease, which was acquired by Smith & Nephew, Inc. in 1999.

Previously, Mr. McBrayer was President and CEO of Osteotech, Inc., a worldwide leader in tissue technology (acquired by Medtronic Inc). He has been responsible for a number of private placements, as well as Osteotech and Exogen’s public offerings.

He received the Thomas Alva Edison Patent Award in 1998 for a biological implant for bone repair that is now a market leading product. Prior to joining Osteotech, he held positions of increasing responsibility for Johnson & Johnson, Inc.

Mr. McBrayer has over 20 years healthcare senior management experience and served as an Infantry Officer Company Commander in the U.S. Army prior to beginning his business career. He is a graduate of the United States Military Academy at West Point.

Mr. McBrayer succeeds Kyle Kerbawy, who will remain as Chairman of the Board.